This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Quidel's CEO Presents At Goldman Sachs Healthcare Conference (Transcript)

Stocks in this article: QDEL

But certainly the seasonality doesn't bother us; it’s the volatility that is a big concern for us. Beginning in 2009, the first step in the process was to bring on board R&D talent, also business development talent. We began creating a pipeline basically from scratch and we focused on a couple of different areas; we focused on a next generation platform to stabilize our presence in the space in which we compete today and then we embarked on molecular diagnostic and the other and I certainly can talk a little bit more about that if you like.

We did effectively three deals if you will. We entered into a collaborative agreement with a company called BioHelix; BioHelix is in the R&D that has now created the world’s first handheld molecular device called AmpliVue and will be launching that first product here in the US in Q4. We also entered into an agreement with Northwestern University who had developed a novel extraction technology that will become the basis for the cartridge that goes into our integrated platform.

And then we also did an acquisition; we spent in early 2010, $130 million on a company called DHI, Diagnostic Hybrids. And the two major things that we got there were R&D synergies they had significant molecular diagnostic and assay development capability and they had an awesome group of scientists who are terrific at characterizing and developing monoclonal antibiotics.

Fast forward to last year, last year was a year in which we finally saw some of the fruits of all that investment. We had four assays cleared here in the United States and to be marketed. Each of those was a 510(k) clearance. And during the period, we also saw a number of technical issues so that in this year, 2012, we should see an acceleration in the topline -- an acceleration in terms of product development and currently we have five assays in clinical trials in the United States and so we expect to see a little bit of productivity gain this year is such that in 2013 we actually see topline acceleration.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs